$13.640
-0.331 (-2.43%)At close
RNA News
RNA Events
Atrium Therapeutics Q2 Revenue at $3M
Reports Q2 revenue $3M vs $3.85M last year. "Our team continues to execute well, achieving FDA clearance of our IND for ATR 1072 and launching Corventis - Atrium's first Phase 1/2 trial and the first clinical study to evaluate a potential disease-modifying treatment for people living with PRKAG2 syndrome," said Kathleen Gallagher, President and Chief Executive Officer of Atrium Therapeutics. "Atrium's precision approach to genetic cardiomyopathies is part of a burgeoning frontier in medicine. Our experienced team is well-positioned to continue advancing and efficiently expanding our pipeline with urgency on behalf of patients and clinicians."
Atrium Therapeutics Earns $15M Milestone Payment from Bristol Myers Squibb
Atrium Therapeutics (RNA) announced it has earned another $15M milestone payment from Bristol Myers Squibb (BMY) based on the successful delivery of a lead compound targeting an undisclosed cardiology indication under the company's ongoing collaboration. The payment is pursuant to Atrium's global licensing and research collaboration with Bristol Myers Squibb (BMS) focused on the discovery, development and commercialization of innovative RNA-based therapies for multiple cardiovascular indications. Under the terms of the agreement, Atrium is eligible to receive up to approximately $1.35B in research and development milestone payments, up to approximately $825M in commercial milestone payments, and tiered royalties up to low double-digits on net sales. BMS will fund all future clinical development, regulatory and commercialization activities coming from the collaboration.
Atrium Therapeutics Gets FDA IND Clearance to Start ATR-1072 Trial
Atrium Therapeutics announced that the FDA has cleared its investigational new drug, or IND, application allowing the company to move forward with its Corventis Phase 1/2 clinical trial designed to evaluate ATR 1072 for the treatment of Protein Kinase AMP-activated non-catalytic subunit Gamma 2 syndrome.
Trump Plans to Fire FDA Commissioner, Biotech Stocks Affected
Catch up on the top industries and stocks that were impacted, or were predicted to be impacted, by the comments, actions and policies of President Donald Trump with this daily recap compiled by The Fly.WAR WITH IRAN:Iran's state news agency IRNA reported Sunday that the country sent its response to the latest proposed U.S. draft agreement for ending the war,The Wall Street Journal. The current phase of negotiations is focused exclusively on the cessation of hostilities in the region, said IRNA, which gave no further details of the Iranian response.Meanwhile, President Donald Trump stated in a Truth Social, "I have just read the response from Iran's so-called 'Representatives.' I don't like it - TOTALLY UNACCEPTABLE! Thank you for your attention to this matter."AI SECURITY ORDER:The White House is planning to order U.S. agencies to partner with AI firms to protect networks from AI-enabled cyber attacks, though the order would stop short of mandating government approval for cutting-edge models, Bloomberg's Maggie Eastland and Courtney Subramanian, citing people familiar with the mater. A draft directive from President Trump would overhaul existing cybersecurity information-sharing programs to include AI companies and address threats posed by the emerging tech, the authors note. Companies in AI software include Alphabet, Meta, OpenAI, and Anthropic.FDA COMMISSIONER:President Trump has signed off on a plan to fire Food and Drug Administration Commissioner Marty Makary, following a tumultuous period for the regulator that included clashes over vaping, abortion and drug policy, The Wall Street Journal's Liz Essley Whyte, citing people familiar with the matter. Makary is seen by other top administration leaders as struggling to manage his agency, sparring frequently with health department officials and at times the White House, the author notes. Biotech stocks that could be impacted by the news include Moderna, Sarepta, Xencor, PTC Therapeutics, Biohaven, Edgewise Therapeutics, Design Therapeutics, Ultragenyx, Avidity Biosciences, Dyne Therapeutics, Wave Life Sciences, MeiraGTx, uniQure, Regenxbio, Novavaxand Lexeo Therapeutics.
本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。